William Febbo

“And good afternoon to everyone joining today's third quarter 2024 earnings call. To get started, while our year-over-year top line revenue grew 30% and came in at $21.3 million, it fell short of our expectations for the quarter.”

“Thank you, operator, and good afternoon to everyone joining today's second quarter 2024 earnings call. While we welcome 36% year-over-year revenue growth, positive cash flow from operations, and a beat for adjusted EBITDA, we fell short on the revenue expectations and consensus midpoint.”

“Thank you, operator, and good afternoon to everyone joining today's first quarter 2024 earnings call. I'm delighted to share today's results, which came in ahead of our April 26 preliminary unaudited earnings announcement.”

“And thank you for joining our conference call to discuss fourth quarter 2023 preliminary unaudited financials. As already communicated, our audit is taking longer than in previous years due to the October 2023 acquisition of Healthy Offers Inc., which does business under the name of Medicx Health.”

“I'm pleased to note that Q3 has been an exciting fiscal and operational turning point for OptimizeRx. As noted in today's press release, the quarter's financial results came in better than initially expected with revenue growing 8% year-over-year to $16.3 million, which is a record third quarter for the company.”